Combination biologic therapy

Clinical and Experimental Rheumatology

Volumn 17, Issue 6 SUPPL. 18, 1999, Pages

  Isaacs, J D ^a,c   Morgan, A W ^a   Strand, V ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b STANFORD UNIVERSITY   (United States)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Anti CD4; Anti TNF ; Biologic therapy; Combination therapy; Immunotherapy

Indexed keywords

ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OKT 4; OKT 8; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY;

EID: 0032720728     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. CAMUSSI G, LUPIA E: The future role of antitumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998; 55: 613-20.
2. SECKINGER P, KLEIN-NULEND J, ALANDER C, THOMPSON RC, DAYER J-M, RAISZ LG: Natural and recombinant human IL-1 ra block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol 1990; 145: 4181-4.
3. WILLIAMS RO, FELDMANN M, MAINI RN: Anti-TNF ameliorates joint disease in murine collagen induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-8.
4. VAN DEN BERG W: Uncoupling of inflammation and joint destruction in arthritis: Pivotal role of IL-1 in destruction. Rheum in Europe 1995; 24 (Suppl. 2): 161.
5. ROUBENOFF R, ROUBENOFF RA, WARD LA, HOLLAND SM, HELLMANN DB: Rheumatoid cachexia: Depletion of lean body mass in RA. Possible association with tumor necrosis factor. J Rheumatol 1992; 19: 1505-10.
6. ROUBENOFF R, ROUBENOFF RA, CANNON JG et al.: Rheumatoid cachexia: Cytokine driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379-86.
7. RUSSELL DA, TUCKER K, CHINOOKOSWONG N, THOMPSON RC, KOHNO T: Combined inhibition of IL-1 and TNF in rodent endotoxemia: improved survival and organ function. J Infect Dis 1995; 171: 1528-38.
8. RUSSELL DA, TUCKER K, KOHNO T, et al.: Inhibition of tumor necrosis factor (TNF) is effective alone or in combination with inhibition of interleukin-1 (IL-1) in reducing joint swelling in rodent bacterial cell wall-induced arthritis. Arthritis Rheum 1994; 37: S279.
9. WILLIAMS RO, FELDMANN M, MAINI RN: Evaluation of anti-IL-1R and anti-TNF therapy in murine collagen arthritis and comparison with combined anti-TNF/anti-CD4 therapy. Arthritis Rheum 1994; 37: S279.
10. JOOSTEN LAB, HELSEN MMA, VAN DE LOO FAJ, VAN DEN BERG WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, Anti-IL-1α/β, and IL-I Ra. Arthritis Rheum 1996; 39: 797-809.
11. BURGER D, REZZONICO R, LI JM et al.: Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: Involvement of membrane-associated cytokines. Arthritis Rheum 1998; 41: 1748-59.
12. KLIMIUK PA, YANG H, GORONZY JJ, WEYAND CM: Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clin Immunol 1999; 90: 65-78.
13. CAWSTON T: Matrix metalloproteinases and TIMPs: Properties and implications for the rheumatic diseases. Molecular Medicine Today 1998; 4: 130-7.
14. AUPPERLE KR, BOYLE DL, HENDRIX M et al.: Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J Pathol 1998; 152: 1091-1098.
15. TANIGUCHI K, KOHSAKA H, INOUE N et al.: Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nature Medicine 1999; 5: 760-7.
16. COBBOLD SP, QIN S, LEONG LYW, MARTIN G, WALDMANN H: Reprogramming the immune System for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 1992; 129: 165-201.
17. QIN S, CODBOLD SP, POPE H, ELLIOTT J, KIOUSSIS D, DAVIES J, WALDMANN H: "Infectious" transplantation tolerance. Science 1993; 259: 974-7.
18. ISAACS JD, WALDMANN H: Regaining self-control - regulation and immunotherapy. Br J Rheumatol 1998; 37: 926-9.
19. WALDMANN H, COBBOLD S: How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu Rev Immunol 1998; 16: 619-44.
20. WALDMANN H, COBBOLD SP: How may immunosuppression lead to tolerance? The war analogy. In: PLOTKIN S and FANTINI B (Eds.): Immune Tolerance: Jenner, Pasteur and Their Successors. Paris. Elsevier, 1997.
21. LANE PJL, BROCKER T: Developmental regulation of dendritic cell function. Curr Op Immunol 1999; 11: 308-13.
22. MAINI RN, PAULUS H, BREEDVELD FC et al.: rHuIL-10 in subjects with active rheumatoid arthritis (RA): A phase I and cytokine response study. Arthritis Rheum 1997; 40: S224.
23. LARSEN CP, ELWOOD ET, ALEXANDER DZ et al.: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-8.
24. ISOBE M, YAGITA H, OKUMURA K, IHARA A: Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125-7.
25. NEWBERRY RD, STENSON WF, LORENZ RG: Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nature Medicine 1999; 5: 900-6.
26. MORGAN AW, HALE G, REBELLO P et al.: Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis: A pilot study. Arthritis Rheum 1997; 40: S81.
27. MORGAN AW, HALE G, WALDMANN H, EMERY P, ISAACS JD: Prolonged combination immunotherapy of RA using CD4 and TNFα blockade - A pilot study. Arthritis Rheum 1998; 41: S138.
28. ISAACS JD, GREENWOOD J, WALDMANN H: Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. J Immunol 1998; 161: 3862-9.
29. ABRAMS JR, LEBWOHL MG, GUZZO CA, et al.: CTLA4Ig mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-52.
30. ISAACS JD: The antiglobulin response to therapeutic antibodies. Semin Immunol 1990; 2: 449-56.
31. ISAACS JD, WATTS RA, HAZLEMAN BL et al.: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992; 340: 748-52.
32. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
33. WILLIAMS RO, MASON LJ, FELDMANN M, MAINI RN: Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994; 91: 2762-6.
34. WILLIAMS RO, GHRAYEB J, FELDMANN M, MAINI RN: Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995; 84: 433-9.
35. BOLT S, ROUTLEDGE E, LLOYD I et al.: The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23: 403-11.
36. MOREAU T, COLES A, WING M et al.: Transient increase in symptoms associated with cy tokine release in patients with multiple sclerosis. Brain 1996; 119: 225-37.
37. BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204.
38. ISAACS JD: Does immunotherapy have a role? In: BIRD HA and SNAITH ML (Eds.): Challenges in Rheumatoid Arthritis. Blackwell Science, Oxford, 1999.
39. TARGAN SR, HANAUER SB, VAN DEVENTER SJH et al.: A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. New Engl J Med 1997; 337: 1029-35.